Novartis Aktie

Kaufen
Verkaufen
95,28 EUR -1,12 EUR -1,16 %
89,32 CHF -1,27 CHF -1,40 %
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln! Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO! Bei einem anderen Broker handeln Smartphone

Marktkap. 185,81 Mrd. EUR

KGV 13,21 Div. Rendite 3,89%

WKN 904278

ISIN CH0012005267

Symbol NVSEF


Novartis Aktie Analyse

22.04.16 Novartis Underweight Morgan Stanley
14.04.16 Novartis Underweight Barclays Capital
12.04.16 Novartis Underweight Morgan Stanley
28.01.16 Novartis Underweight Barclays Capital
15.01.16 Novartis Underweight Barclays Capital
14.10.14 Novartis Underweight Morgan Stanley
16.09.14 Novartis Underweight Morgan Stanley
21.07.14 Novartis Underweight Morgan Stanley
20.06.14 Novartis Underweight Morgan Stanley
02.06.14 Novartis Underweight Morgan Stanley
15.05.14 Novartis Underweight Morgan Stanley
29.04.14 Novartis Underweight Morgan Stanley
23.04.14 Novartis Underweight Barclays Capital
14.03.14 Novartis Underweight Morgan Stanley
10.03.14 Novartis Underweight Barclays Capital
30.01.14 Novartis verkaufen Barclays Capital
24.01.14 Novartis verkaufen Barclays Capital
18.10.13 Novartis verkaufen Barclays Capital
16.09.13 Novartis verkaufen Barclays Capital
14.01.13 Novartis verkaufen Vontobel Research
11.01.13 Novartis verkaufen Vontobel Research
11.12.12 Novartis reduce Vontobel Research
21.11.12 Novartis reduce Vontobel Research
08.11.12 Novartis reduce Vontobel Research
07.11.12 Novartis reduce Vontobel Research
26.10.12 Novartis reduce Vontobel Research
25.10.12 Novartis reduce Vontobel Research
24.10.12 Novartis underperform Cheuvreux SA
17.10.12 Novartis reduce Vontobel Research
16.10.12 Novartis underperform Banc of America Securities-Merrill Lynch
12.10.12 Novartis reduce Vontobel Research
08.10.12 Novartis reduce Vontobel Research
01.10.12 Novartis reduce Vontobel Research
24.09.12 Novartis reduce Vontobel Research
13.09.12 Novartis reduce Vontobel Research
11.09.12 Novartis underperform Banc of America Securities-Merrill Lynch
05.09.12 Novartis reduce Vontobel Research
03.09.12 Novartis reduce Vontobel Research
30.08.12 Novartis reduce Vontobel Research
28.08.12 Novartis reduce Vontobel Research
27.08.12 Novartis reduce Vontobel Research
24.04.12 Novartis underperform Cheuvreux SA
07.02.12 Novartis underperform Banc of America Securities-Merrill Lynch
26.01.12 Novartis underperform Cheuvreux SA
29.11.11 Novartis underperform Cheuvreux SA
25.11.09 Novartis underperform Cheuvreux SA
12.11.09 Novartis underweight Barclays Capital
18.09.08 Novartis underperform Cheuvreux SA
09.09.08 Novartis underperform Cheuvreux SA
16.07.08 Novartis underperform Credit Suisse Group
Werbung